Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement

Core Insights - Spartan Capital Securities LLC successfully completed a private placement for Lipella Pharmaceuticals Inc., raising $1,722,000 through the sale of up to 6,000,000 Series B non-voting convertible preferred stock [1][2][3] Group 1: Transaction Details - The private placement closed on December 16, 2024, and the proceeds will support Lipella's clinical pipeline and general corporate purposes [2] - Spartan Capital Securities acted as the sole placement agent for this transaction, highlighting its role in facilitating impactful investment opportunities [3] Group 2: Company Background - Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on addressing significant unmet medical needs with safe and effective therapies [2] - Spartan Capital Securities, LLC is a full-service investment banking firm known for its expertise in capital raising, strategic advisory, and asset management [7]